Company: PCRX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001104659-25-041219
Chunk: 1

Company: Pacira BioSciences, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 1
---
 and we see significant momentum for further value creation.                                                                                                                                                                                                                                                
 As part of our steadfast commitment to transform the lives of patients, we expanded clinician access to our safe and effective opioid-sparing products by securing NOPAIN Act reimbursement for EXPAREL and ioveraº and by facilitating coverage of EXPAREL through the introduction of its new product-specific J-code. We also won the FDA’s first-ever RMAT designation in osteoarthritis for our promising and potentially transformative candidate PCRX-201, enabling us to accelerate its development and pathway to market. 
 I believe our 5x30 strategy will create value for stockholders through two strategic imperatives: delivering growth in our commercial-based business and building an innovative pipeline. We’re already progressing on these initiatives with the acquisition of GQ Bio Therapeutics GmbH in February 2025. GQ Bio’s HCAd platform has generated encouraging clinical data with PCRX-201 and will further enhance our ability to address unmet patient needs.                                                                      
 I am inspired by the hard work of our highly committed team and am confident in our ability to capitalize on the opportunities in front of us as we grow and transform even more patients’ lives through the delivery of our trusted products.                                                                                                                                                                                                                                                                                     | ​ | ​ |   | ​ | ​ |
| ​ | ​ | ​ | ​ | ​ | FRANK D. LEEChief Executive Officer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | ​ | ​ | ​ | ​ | ​ |

* Included in net loss in 2024 was a $163.2 million goodwill impairment based upon an assessment that the fair value of goodwill was less than its carrying value. ** Adjusted EBIDA is a non-GAAP financial measure. See “Appendix A—Reconciliation of U.S. GAAP Net Income (Loss) to Adjusted EBITDA” for the definition of Adjusted EBITDA and a reconciliation to the most directly comparable GAAP measure.

| ​ |                                                                                                                                                                                                                                                                                                                                                           | ​ | ​ | ​ |                                                                                                                                                                                                                                | ​ | ​ | ​ |                                                                                                                                                                                                                                                                                                                                                                                                                            | ​ |
| ​ | EXPAREL®(bupivacaine liposome injectable suspension) is an extended-release local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. EXPAREL turns off the body’s pain signals, numbing the area where surgery has occurred for several days following the procedure. 
 EXPAREL is the only non-opioid, single-dose,